Skip to main content

Celgene Corporation



) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 0.4%. By the end of trading, Celgene Corporation fell 65 cents (-0.9%) to $68.25 on average volume. Throughout the day, three million shares of Celgene Corporation exchanged hands as compared to its average daily volume of three million shares. The stock ranged in price between $68.11-$69.23 after having opened the day at $68.74 as compared to the previous trading day's close of $68.90. Other company's within the Drugs industry that declined today were:

Chelsea Therapeutics International



), down 31.3%,

ARCA biopharma



), down 21.7%,




), down 17.4%, and

Scroll to Continue

TheStreet Recommends




), down 12.8%.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $30.28 billion and is part of the

health care

sector. The company has a P/E ratio of 21.4, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 1.7% year to date as of the close of trading on Wednesday. Currently there are 22 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Celgene Corporation as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

Prima Biomed Ltd. ADR



), up 23.5%,

Synta Pharmaceuticals



), up 15.6%,




), up 14.9%, and

Senesco Technologies



), up 13.3%, were all gainers within the drugs industry with




) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech